Docetaxel is under clinical development by Nanology and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase II drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Docetaxel is under development for the treatment of muscle-invasive bladder cancer, non-muscle invasive bladder cancer, breast cancer, prostate carcinoma, urothelial carcinoma and renal cell carcinoma. The drug candidate is a sterile nanoparticle suspension which is administered intratumorally and intravascularly. The drug candidate is developed based on naked nanoparticle platform technology. It acts by targeting tubulin.It was also under development for treatment of breast cancer.
Nanology operates as a clinical stage pharmaceutical development company formed by the collaboration of DFB Pharmaceuticals, CritiTech, and US Biotest to advance its patented submicron particle production technology platform for the treatment of cancer and other serious illnesses. The company’s program includes clinical trials in ovarian, prostate, and pancreatic cancers, pancreatic cysts, cutaneous metastases, and actinic keratosis under affiliate, Soria. In addition, nonclinical studies via nebulized inhalation are underway for the treatment of lung cancer. Nanology is headquartered in Fort Worth, Texas, the US.
For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.